|Day Low/High||113.15 / 113.40|
|52 Wk Low/High||34.53 / 114.20|
Data show that 65 percent of participants demonstrated the maximal improvement in the clinical trial's primary endpoint, bilateral multi-luminance mobility testing (MLMT), at year one
Investors in Spark Therapeutics Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 18th contracts and identified one put and one call contract of particular interest.
Voretigene neparvovec has the potential to be the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the U.S.
Breadth has a small window to improve from the poor and lagging action we saw last week.
In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $64.73, changing hands for $64.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Second milestone achieved under 2014 global license agreement with Pfizer
I spent the weekend with thousands of blood disease researchers. This is what happened.
Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.
Conference call also scheduled for Monday, Dec. 5 at 8 a.m. ET
The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.